Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
60 participants
INTERVENTIONAL
2003-08-31
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ABT-751
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Recurrent tumor.
* At least 6 weeks post-nephrectomy.
* Able to tolerate normal activities of daily living.
* Adequate bone marrow, kidney, and liver function.
Exclusion Criteria
* Anti-tumor therapy within 4 weeks of the start of ABT-751 administration.
* CNS metastasis.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Helen Eliopoulos, M.D.
Role: STUDY_DIRECTOR
Abbott
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Cancer Research Center
Tucson, Arizona, United States
UCLA School of Medicine
Los Angeles, California, United States
Clinical Trials + Research Associates
Montebello, California, United States
US Oncology Inc Rocky Mountain Cancer Centers
Denver, Colorado, United States
Oncology Hematology Group of South Florida
Miami, Florida, United States
US Oncology Inc Florida Cancer Institute
New Port Richey, Florida, United States
US Oncology Inc Ocala Oncology Center
Ocala, Florida, United States
US Oncology Inc Cancer Centers of Florida, P.A.
Orlando, Florida, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
US Oncology Inc Raleigh Hematology Oncology Clinic
Cary, North Carolina, United States
US Oncology Inc Dayton Oncology & Hematology P.A.
Kettering, Ohio, United States
US Oncology Inc Cancer Care Accociates-Mercy Campus
Oklahoma City, Oklahoma, United States
US Oncology Inc Cancer Centers of the Carolinas
Greenville, South Carolina, United States
West Cancer Clinic
Memphis, Tennessee, United States
Vanderbilt Ingram Cancer Center
Nashville, Tennessee, United States
US Oncology Inc Tyler Cancer Center
Tyler, Texas, United States
US Oncology Inc Cancer Care Northwest-North
Spokane, Washington, United States
US Oncology Inc Northwest Cancer Specialists
Vancouver, Washington, United States
B.C. Vancouver Cancer Agency
Vancouver, British Columbia, Canada
Queen Elizabeth II Health Science Centre
Halifax, Nova Scotia, Canada
McMaster University
Hamilton, Ontario, Canada
McGill University
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M02-416
Identifier Type: -
Identifier Source: org_study_id
NCT00080717
Identifier Type: -
Identifier Source: nct_alias